Biological sample preservation
Atelerix
Cell preservation is moving towards a space test. A new partnership asks whether hydrogel storage can reduce the burden of carrying living samples. [1] analysis
Your heat score
Your personal rating, from 0 to 100.
Set your score
Saved only in this browser. Your rating is an opinion, separate from the evidence.
From inputs to the laboratory buyer
Schematic flow of input categories, products and selling channels. It does not identify undisclosed suppliers.
Reading direction. No quantity or physical timing is implied.
Select a participant or connection. Its explanation stays alongside.
Ready to explore.
Alginate and buffers are input categories; upstream vendor identities are not established.
analysis
A category is not a verified supplier contract.
N8 Research Partnership: Atelerix history
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceUnnamed input suppliers
analysis
Alginate and buffers are input categories; upstream vendor identities are not established. [18] [15]
A category is not a verified supplier contract.
N8 Research Partnership: Atelerix history
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceBeadReady combines gels and buffers for encapsulation and release.
company claim
The detailed manufacturing process and production economics are undisclosed.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourcePreservation kits
company claim
BeadReady combines gels and buffers for encapsulation and release. [15]
The detailed manufacturing process and production economics are undisclosed.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix offers products under its published sale terms.
company claim
Terms do not disclose actual sales volumes.
Atelerix terms of sale
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix, the seller
company claim
Atelerix offers products under its published sale terms. [4]
Terms do not disclose actual sales volumes.
Atelerix terms of sale
Publication date not recorded; Accessed 2026-11-01
Open original sourceThe company describes a network serving local research markets.
company claim
Specific contractual commitments are not mapped.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceAuthorised distributor
company claim
The company describes a network serving local research markets. [16]
Specific contractual commitments are not mapped.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceResearch laboratories and bioscience organisations are the stated customer context.
company claim
This category does not imply a particular paid contract.
Atelerix selected customer testimonials
Publication date not recorded; Accessed 2026-11-01
Open original sourceLaboratory buyer
company claim
Research laboratories and bioscience organisations are the stated customer context. [19]
This category does not imply a particular paid contract.
Atelerix selected customer testimonials
Publication date not recorded; Accessed 2026-11-01
Open original sourceGel and buffer inputs form the materials used in the BeadReady preservation kit.
analysis
Schematic dependency; purchase orders were not inspected.
Gel and buffer inputs form the materials used in the BeadReady preservation kit.
The kit needs materials for forming the hydrogel and subsequently releasing the encapsulated cells.
These inputs become an offered kit; upstream purchase orders and vendor identities are not established.
N8 Research Partnership: Atelerix history
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceMaterial dependency
analysis
Unnamed input suppliers → Preservation kits
Gel and buffer inputs form the materials used in the BeadReady preservation kit. [18] [15]
- What happens
- Gel and buffer inputs form the materials used in the BeadReady preservation kit.
- Why it matters
- The kit needs materials for forming the hydrogel and subsequently releasing the encapsulated cells.
- What follows
- These inputs become an offered kit; upstream purchase orders and vendor identities are not established.
Schematic dependency; purchase orders were not inspected.
N8 Research Partnership: Atelerix history
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceBeadReady is a preservation kit offered by Atelerix to research buyers.
company claim
No production cadence is implied.
BeadReady is a preservation kit offered by Atelerix to research buyers.
This links the kit to its seller; it does not depict a shipment from the kit to the company.
Buyers can approach Atelerix or an authorised distributor; production volumes are not established.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceOffered by Atelerix
company claim
Preservation kits → Atelerix, the seller
BeadReady is a preservation kit offered by Atelerix to research buyers. [15]
- What happens
- BeadReady is a preservation kit offered by Atelerix to research buyers.
- Why it matters
- This links the kit to its seller; it does not depict a shipment from the kit to the company.
- What follows
- Buyers can approach Atelerix or an authorised distributor; production volumes are not established.
No production cadence is implied.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix makes its products available through an authorised distributor route alongside direct sales.
company claim
Physical stock ownership and payment terms are not established.
Atelerix makes its products available through an authorised distributor route alongside direct sales.
Distributors provide a local commercial route into research markets served by their organisations.
A researcher can approach the local channel; stock ownership and wholesale payment arrangements remain unknown.
Atelerix terms of sale
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceDistribution route
company claim
Atelerix, the seller → Authorised distributor
Atelerix makes its products available through an authorised distributor route alongside direct sales. [4] [16]
- What happens
- Atelerix makes its products available through an authorised distributor route alongside direct sales.
- Why it matters
- Distributors provide a local commercial route into research markets served by their organisations.
- What follows
- A researcher can approach the local channel; stock ownership and wholesale payment arrangements remain unknown.
Physical stock ownership and payment terms are not established.
Atelerix terms of sale
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceA distributor offers local researchers a route to purchase Atelerix preservation products.
company claim
No territory exclusivity or measured sell-through is implied.
A distributor offers local researchers a route to purchase Atelerix preservation products.
This connects the product offering with laboratories in the distributor's market.
The laboratory must still choose a suitable product and procedure; no local sales volume is established.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceLocal product sale
company claim
Authorised distributor → Laboratory buyer
A distributor offers local researchers a route to purchase Atelerix preservation products. [16]
- What happens
- A distributor offers local researchers a route to purchase Atelerix preservation products.
- Why it matters
- This connects the product offering with laboratories in the distributor's market.
- What follows
- The laboratory must still choose a suitable product and procedure; no local sales volume is established.
No territory exclusivity or measured sell-through is implied.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceA customer can order BeadReady directly from Atelerix through its product offering.
company claim
No order quantity is depicted.
A customer can order BeadReady directly from Atelerix through its product offering.
This route connects the laboratory with the manufacturer without requiring a distributor purchase.
The laboratory follows the relevant kit instructions and assesses suitability for its own samples.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceDirect product sale
company claim
Atelerix, the seller → Laboratory buyer
A customer can order BeadReady directly from Atelerix through its product offering. [15]
- What happens
- A customer can order BeadReady directly from Atelerix through its product offering.
- Why it matters
- This route connects the laboratory with the manufacturer without requiring a distributor purchase.
- What follows
- The laboratory follows the relevant kit instructions and assesses suitability for its own samples.
No order quantity is depicted.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceComplete participants, relationships and sources
Unnamed input suppliers
analysis
Alginate and buffers are input categories; upstream vendor identities are not established. [18] [15]
A category is not a verified supplier contract.
N8 Research Partnership: Atelerix history
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourcePreservation kits
company claim
BeadReady combines gels and buffers for encapsulation and release. [15]
The detailed manufacturing process and production economics are undisclosed.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix, the seller
company claim
Atelerix offers products under its published sale terms. [4]
Terms do not disclose actual sales volumes.
Atelerix terms of sale
Publication date not recorded; Accessed 2026-11-01
Open original sourceAuthorised distributor
company claim
The company describes a network serving local research markets. [16]
Specific contractual commitments are not mapped.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceLaboratory buyer
company claim
Research laboratories and bioscience organisations are the stated customer context. [19]
This category does not imply a particular paid contract.
Atelerix selected customer testimonials
Publication date not recorded; Accessed 2026-11-01
Open original sourceMaterial dependency
analysis
Unnamed input suppliers → Preservation kits
Gel and buffer inputs form the materials used in the BeadReady preservation kit. [18] [15]
- What happens
- Gel and buffer inputs form the materials used in the BeadReady preservation kit.
- Why it matters
- The kit needs materials for forming the hydrogel and subsequently releasing the encapsulated cells.
- What follows
- These inputs become an offered kit; upstream purchase orders and vendor identities are not established.
Schematic dependency; purchase orders were not inspected.
N8 Research Partnership: Atelerix history
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceOffered by Atelerix
company claim
Preservation kits → Atelerix, the seller
BeadReady is a preservation kit offered by Atelerix to research buyers. [15]
- What happens
- BeadReady is a preservation kit offered by Atelerix to research buyers.
- Why it matters
- This links the kit to its seller; it does not depict a shipment from the kit to the company.
- What follows
- Buyers can approach Atelerix or an authorised distributor; production volumes are not established.
No production cadence is implied.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceDistribution route
company claim
Atelerix, the seller → Authorised distributor
Atelerix makes its products available through an authorised distributor route alongside direct sales. [4] [16]
- What happens
- Atelerix makes its products available through an authorised distributor route alongside direct sales.
- Why it matters
- Distributors provide a local commercial route into research markets served by their organisations.
- What follows
- A researcher can approach the local channel; stock ownership and wholesale payment arrangements remain unknown.
Physical stock ownership and payment terms are not established.
Atelerix terms of sale
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceLocal product sale
company claim
Authorised distributor → Laboratory buyer
A distributor offers local researchers a route to purchase Atelerix preservation products. [16]
- What happens
- A distributor offers local researchers a route to purchase Atelerix preservation products.
- Why it matters
- This connects the product offering with laboratories in the distributor's market.
- What follows
- The laboratory must still choose a suitable product and procedure; no local sales volume is established.
No territory exclusivity or measured sell-through is implied.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceDirect product sale
company claim
Atelerix, the seller → Laboratory buyer
A customer can order BeadReady directly from Atelerix through its product offering. [15]
- What happens
- A customer can order BeadReady directly from Atelerix through its product offering.
- Why it matters
- This route connects the laboratory with the manufacturer without requiring a distributor purchase.
- What follows
- The laboratory follows the relevant kit instructions and assesses suitability for its own samples.
No order quantity is depicted.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceScope. Supplier names, manufacturing locations, volumes and channel margins are not established. Arrows represent the stated relationship, not shipment frequency or guaranteed performance.
Diagram
BeadReady, from kit to use
Atelerix preserves cells in hydrogel beads, with release or use in the gel depending on the application.
Use Enlarge drawing for detail. The tour caption explains the selected elements.
Step 1 of 6: Explore the current kit. Static diagram.
Explore the current kit
BeadReady encapsulates cells in hydrogel. The company describes storage, release for use, and imaging or co-culture with cells retained in gel. The separate study below covers release and subsequent assays.
Full step and context
BeadReady encapsulates cells in hydrogel. The company describes storage, release for use, and imaging or co-culture with cells retained in gel. The separate study below covers release and subsequent assays.
Reduced motion is on. Use Previous and Next to explore the steps.
Guided reading, not physical motion.
Explore the diagram
Hover or focus an element to preview its evidence. Click or tap to pin it. Select another element or clear the selection to continue.
Choose an element to inspect its evidence.
BeadReady: the current kit
Current kit workflow and two distinct uses, before a separate historical study example.
company claim. Atelerix offers BeadReady hydrogel kits for cell encapsulation, storage, imaging and co-culture. Cells can remain in the gel for some uses; the study below examines release and subsequent assays.
Drawing. company claim.
Source location. Current process schematic and imaging/co-culture product uses, inspected 1 November 2026 [15]
Limitation. Schematic bead count and routes. Storage conditions and compatibility require a cell-specific protocol; no clinical validation is implied.
LABORATORY STUDY | 2022
Study population and publication year.
verified. A 2022 laboratory study used adipose-derived stromal cells from three donors, expanded in either foetal bovine serum or human platelet lysate medium.
Drawing. observed.
Source location. Figure 1 and caption, page 8; Results opening, page 7 [7]
Limitation. Three donors and two expansion media; not every cell type.
01 Encapsulate
Alginate bead outline contains illustrative cell symbols; the label identifies the study kit.
verified. Researchers mixed adipose-derived stromal cells with alginate and formed beads using the BeadReady kit provided by Atelerix.
Drawing. simplification.
Source location. Section 2.3, page 4; Figure 1, page 8 [7]
Limitation. Geometry and symbol counts are illustrative. The kit instructions are summarised, not reproduced.
02 Store in medium
Sequence arrow leads to storage in a sealed tube; labels give the study temperature range and sampling times.
verified. Beads were stored in medium in sealed tubes away from light at 10 to 20 °C, then sampled after 30 minutes, 5 days or 12 days.
Drawing. simplification.
Source location. Section 2.3, page 4; Figure 1 and caption, page 8 [7]
Limitation. The arrow expresses procedure order, not speed. Times are sampled conditions, not a guaranteed shelf life.
03 Release the cells
Sequence arrow and separate cell symbols denote buffer release, washing and resuspension.
verified. Dissolution buffer released the cells. Researchers washed and resuspended them before assessing recovery and viability separately.
Drawing. simplification.
Source location. Section 2.3, page 4; Figure 1, page 8 [7]
Limitation. No dissolution chemistry, release rate or quantitative recovery is depicted.
Recovery
One assessment branch denotes quantification of recovered cells.
verified. Dissolution buffer released the cells. Researchers washed and resuspended them before assessing recovery and viability separately.
Drawing. observed.
Source location. Section 2.3, page 4; Figure 2A and caption, page 9 [7]
Limitation. Branching denotes separate assessments, not a physical sample split or an assay result.
Viability
The second assessment branch denotes cell viability assessment.
verified. Dissolution buffer released the cells. Researchers washed and resuspended them before assessing recovery and viability separately.
Drawing. observed.
Source location. Section 2.3, page 4; Figure 2B and caption, page 9 [7]
Limitation. No viability percentage is encoded. Viability does not establish clinical potency.
Separate measurements, not equivalent outcomes.
Visible boundary separates recovery from viability and declares schematic scale.
analysis. Recovery and viability are distinct measurements. This schematic reports the laboratory workflow, not a validated clinical or transport service.
Drawing. simplification.
Source location. Figure 2A-B and caption, page 9; Discussion, pages 17-20 [7]
Limitation. Additional characterisation assays and the non-encapsulated comparator are omitted from this focused workflow, not from the study.
Step timings allow time to read. They do not represent physical speed or duration.
Explore the current kit
BeadReady encapsulates cells in hydrogel. The company describes storage, release for use, and imaging or co-culture with cells retained in gel. The separate study below covers release and subsequent assays.
The study
A 2022 laboratory study used adipose-derived stromal cells from three donors, expanded in either foetal bovine serum or human platelet lysate medium.
1. Encapsulate
Researchers mixed adipose-derived stromal cells with alginate and formed beads using the BeadReady kit provided by Atelerix.
2. Store
Beads were stored in medium in sealed tubes away from light at 10 to 20 °C, then sampled after 30 minutes, 5 days or 12 days.
3. Release
Replace the storage medium with dissolution buffer, then wash and resuspend the released cells.
4. Assess separately
Quantify recovered cells and assess their viability separately. A high viability among recovered cells does not establish complete cell recovery.
Current company workflow first: encapsulate cells in hydrogel beads, store or transport under an appropriate protocol, then release the cells or use them in the gel for imaging/co-culture. Below, a separate 2022 laboratory example follows encapsulation, controlled storage, dissolution and separate recovery and viability assays. The study does not validate every current product use.
Limitations.
- Laboratory study of adipose-derived stromal cells from three donors, not clinical effectiveness or transport qualification. Recovery and viability are different measurements. The 10 to 20 °C range and sampling times describe this experiment, not a universal product specification or guaranteed shelf life. Cell counts, vessel shapes and spacing are schematic. Additional assays and the non-encapsulated comparator are omitted. Publisher update status could not be checked during this audit.
Evidence
- verified. A 2022 laboratory study used adipose-derived stromal cells from three donors, expanded in either foetal bovine serum or human platelet lysate medium. [7]
- verified. Researchers mixed adipose-derived stromal cells with alginate and formed beads using the BeadReady kit provided by Atelerix. [7]
- verified. Beads were stored in medium in sealed tubes away from light at 10 to 20 °C, then sampled after 30 minutes, 5 days or 12 days. [7]
- verified. Dissolution buffer released the cells. Researchers washed and resuspended them before assessing recovery and viability separately. [7]
- analysis. Recovery and viability are distinct measurements. This schematic reports the laboratory workflow, not a validated clinical or transport service. [7]
- company claim. Atelerix offers BeadReady hydrogel kits for cell encapsulation, storage, imaging and co-culture. Cells can remain in the gel for some uses; the study below examines release and subsequent assays. [15]
Diagram elements
- current-product: company claim. Current kit workflow and two distinct uses, before a separate historical study example. Current process schematic and imaging/co-culture product uses, inspected 1 November 2026 [15] Limitation. Schematic bead count and routes. Storage conditions and compatibility require a cell-specific protocol; no clinical validation is implied.
- study-scope: observed. Study population and publication year. Figure 1 and caption, page 8; Results opening, page 7 [7] Limitation. Three donors and two expansion media; not every cell type.
- bead: simplification. Alginate bead outline contains illustrative cell symbols; the label identifies the study kit. Section 2.3, page 4; Figure 1, page 8 [7] Limitation. Geometry and symbol counts are illustrative. The kit instructions are summarised, not reproduced.
- store: simplification. Sequence arrow leads to storage in a sealed tube; labels give the study temperature range and sampling times. Section 2.3, page 4; Figure 1 and caption, page 8 [7] Limitation. The arrow expresses procedure order, not speed. Times are sampled conditions, not a guaranteed shelf life.
- release: simplification. Sequence arrow and separate cell symbols denote buffer release, washing and resuspension. Section 2.3, page 4; Figure 1, page 8 [7] Limitation. No dissolution chemistry, release rate or quantitative recovery is depicted.
- recovery: observed. One assessment branch denotes quantification of recovered cells. Section 2.3, page 4; Figure 2A and caption, page 9 [7] Limitation. Branching denotes separate assessments, not a physical sample split or an assay result.
- viability: observed. The second assessment branch denotes cell viability assessment. Section 2.3, page 4; Figure 2B and caption, page 9 [7] Limitation. No viability percentage is encoded. Viability does not establish clinical potency.
- study-boundary: simplification. Visible boundary separates recovery from viability and declares schematic scale. Figure 2A-B and caption, page 9; Discussion, pages 17-20 [7] Limitation. Additional characterisation assays and the non-encapsulated comparator are omitted from this focused workflow, not from the study.
Interactive 3D explainer
How a gel holds a cell sample
Explore the photographed reagent kit, then a separate published explanation of bead formation, storage and optional cell release.
Controls
Jump to a step
Hover the model or choose a part
No part selected
Atelerix
Explore the photographed reagent kit, then a separate published explanation of bead formation, storage and optional cell release.
Kit appearance follows a company photo. Enlarged scenes explain the 2022 study, not a current protocol. Cell symbols, scale and animation time are illustrative.
Source for this explanation ↗The static explanation below is available without 3D or JavaScript.
Evidence boundary. Kit appearance follows a company photo. Enlarged scenes explain the 2022 study, not a current protocol. Cell symbols, scale and animation time are illustrative.
Static explanation and all component roles
- Photographed kit: a stationary explanatory view, not measured motion.
- Inside one bead: a stationary explanatory view, not measured motion.
- 2022 bead formation: a stationary explanatory view, not measured motion.
- Storage environment: a stationary explanatory view, not measured motion.
- Optional release: a stationary explanatory view, not measured motion.
- Kit and sample vessel
- The kit contains separate reagents. A sample vessel holds beads during the published procedure.
Purpose. Packaging, reagents and the sample container have different roles.
Normalised appearance from a dated kit photo. The illustrative sample vessel is not claimed to be supplied.company claim | inspected 2026-11-01 | Source 1 | Source 2 | Source 3
- Cell sample
- Cells are held within gel, or recovered into liquid for another workflow.
Purpose. These are the biological samples whose recovery, viability and function need separate assessment.
Illustrative cell symbols and count, not microscopic morphology or measured survival. - Hydrogel matrix
- The matrix immobilises several cells within a bead.
Purpose. The gel provides a distinct environment around the cells. Some uses retain them inside.
No polymer structure, pore dimensions or crosslink chemistry is reconstructed.analysis | inspected 2026-11-01 | Source 1 | Source 2 | Source 3
- Surrounding medium
- Liquid surrounds formed beads during storage in the 2022 procedure.
Purpose. Cells retain metabolism. Storage does not completely pause their biology.
No universal storage condition, shelf life or cell compatibility is implied. - Dissolution buffer
- Buffer removes the matrix when a workflow needs recovered cells.
Purpose. Other workflows can image or co-culture cells while they remain in gel.
Release is optional. This illustration does not predict dissolution speed, recovery or viability.analysis | inspected 2026-11-01 | Source 1 | Source 2 | Source 3
- Published gel-forming step
- The 2022 study added cell-containing alginate droplets to gelation solution.
Purpose. This turns a fluid mixture into beads containing cells.
Historical procedure only. Conflicting current page descriptions cannot establish an exact current protocol.analysis | inspected 2026-11-01 | Source 1
company claim; analysis geometry · Atelerix source. Source inspection dates are listed for each component. Publication date is recorded in the dossier source list where established. Every shape is an explanatory simplification; the scene does not establish engineering performance.
Capital, customers and market direction
Money and market
Evidence checked to . Company finances and wider-market indicators are kept separate.
Announced financing
GBP 750kThe company announced financing with ACF Investors and o2h Ventures in the article dated 28 January 2025. [F1]
The URL has a different date. This is historical financing, not current cash.
company claimCommercial hurdle
Repeat ordersFunding was directed towards sales and converting early adopters into customers. The financial test is repeat purchases per validated sample workflow. [F1]
No retention cohort, realised price or gross margin was disclosed in the announcement.
analysisLogistics market signal
USD 48.971mCryoport reported Q2 2026 revenue, compared with USD 45.454m a year earlier. Its reported growth was 8%. [F2]
Broad cold-chain competitor context. Cryoport growth does not establish demand for ambient-preservation products.
verifiedCash and runway
Not disclosedNot established. Current cash, committed facilities, monthly cash burn and a funded milestone plan have not been obtained.
A financing announcement is not the cash balance. No runway estimate is shown.
analysisWhat the market signal means
Growing activity, but switching must pay
Cryoport reports rising life-sciences logistics activity. Atelerix must prove that usable-sample recovery, labour and shipping costs justify changing an established workflow. [F1] [F2]
Company claims of shipment savings are not a matched customer cost study.
analysisCryoport quarterly revenue
Same quarter in successive years, continuing operations as presented by issuer.
USD thousand. Bars start at zero.
Cryoport is a diversified alternative provider; values are not Atelerix revenue. [F2]
Source location: Revenue by business table, Total Revenue, Q2 2025 and Q2 2026. Reported values; no forecast or startup valuation.
Questions that change the financial case
- What proportion of first orders converts to repeat paid purchases?
- What is contribution margin after quality control, distributor discounts and support?
- Does each target sample type show a measured total-workflow saving against its actual alternative?
Financial overview sources and dates
- F1 Atelerix financing announcement
Published 2025-01-28 · Accessed 2026-11-01
- F2 Cryoport Q2 2026 results
Published 2026-08-06 · Accessed 2026-11-01
The development
On 27 October, Atelerix announced a two-year memorandum with Frontier Space to validate sample preservation for microgravity research, targeting launch opportunities in 2027. This is a proposed validation programme, not a completed orbital test. [1] company claim
Claims and evidence
Cell preservation is moving towards a space test. A new partnership asks whether hydrogel storage can reduce the burden of carrying living samples. [1]
analysisOn 27 October, Atelerix announced a two-year memorandum with Frontier Space to validate sample preservation for microgravity research, targeting launch opportunities in 2027. This is a proposed validation programme, not a completed orbital test. [1]
company claimCompanies House records Atelerix Limited as active and privately incorporated in 2017. The control register contains a no-registrable-controller statement; it is not a complete cap table. [2] [3]
verifiedThe company uses alginate hydrogels to hold biological samples during storage and transport, then releases them for use. Suitability depends on the sample and protocol. [6]
company claimA 2022 study tested BeadReady with cells from three donors at 10 to 20 degrees C. Recovery fell with time. The company supplied kits; authors declared no conflict. These terrestrial experiments do not establish space performance. [7]
verifiedPublished sale terms restrict the standard product licence to internal research. Other commercial uses require an additional licence. This is not evidence of clinical approval. [4]
company claim
Assessment
| Topic | Reading and evidence |
|---|---|
| Product and mechanism | Preservation is a consumable-and-protocol proposition. The business must demonstrate usable recovery for each customer's sample, rather than rely on a universal room-temperature claim. [6] analysis |
| Customers and buying process | The partnership addresses organisations sending biological samples on space missions. A mission-specific qualification and agreed acceptance criteria would precede a credible operating case. [1] analysis |
| Commercial proof | The memorandum establishes intent to collaborate. Paid orders, minimum volumes, exclusivity and mission bookings were not disclosed. [1] analysis |
| Pricing or economics | Not established. Obtain kit price at volume, release labour, usable sample recovery and total transport cost against the customer's existing workflow. unknown |
| Competitors and substitutes | Cryogenic transport is the stated alternative. Compare total mission mass and sample quality using matched samples and a defined control protocol. [1] analysis |
| Distribution | Current sale terms cover direct and authorised-distributor purchases. Commercial expansion may require separate licences, not only more kit sales. [4] analysis |
| Intellectual property or defensibility | The company reports a patent history. Patent numbers, remaining terms, assignment and freedom to operate need a dedicated record review. [5] analysis |
| Manufacturing or operational scaling | Not established. Obtain lot consistency, shelf-life, sterility assurance, release specifications and production capacity. unknown |
| Regulation | Research-use terms do not authorise treatment or diagnostics. Establish the permitted use and mission-specific biological handling requirements before estimating a market. [4] analysis |
| Capital needs | Not established. The memorandum discloses neither trial funding nor runway. Obtain programme budget, payment milestones and funding commitments. unknown |
| Key risks | A useful preservation method must retain enough functional material after release. Orbit adds an untested environment; reduced transport mass remains an objective. [1] [7] analysis |
| Next falsifiable milestone | A published matched-control protocol followed by mission results would test the thesis. A launch booking alone would not. [1] analysis |
| Team and history | The company traces its origin to Newcastle research and incorporation in 2017. The technology predates this partnership; the new question is its space application. [5] [2] analysis |
| Public-market context | The comparisons below use historical standalone BioLife figures, Cryoport continuing operations and Repligen as the current parent of BioLife. Their different product mixes and reporting boundaries limit comparisons; no Atelerix valuation or comparable multiple is established. [8] [9] [10] analysis |
Recovery declines with storage time
Scale: 0 to 100 % of initial cells recovered
| Item | Value (% of initial cells recovered) | Date and evidence |
|---|---|---|
| 30 minutes | 77 | 2022-12-14 verified [7] |
| 5 days | 77 | 2022-12-14 verified [7] |
| 12 days | 50 | 2022-12-14 verified [7] |
Opinion
A small consumable can matter if it removes costly mission infrastructure without sacrificing usable samples. The partnership is interesting because it offers a route to testing that trade-off. I would look for a matched-control result and a paying repeat user.
Limits. The agreement is early. No orbital result, space revenue or demonstrated mission saving was obtained. Poor recovery after realistic transport would weaken the case even if surviving cells remain viable.
opinionCommercial picture · 2026-11-01
Competition, costs and demand
Public-source comparison of preservation products, logistics and operating economics. Figures are dated benchmarks, not Atelerix cash-flow forecasts. Competitor coverage is bounded and non-exhaustive.
How orders become a preservation service
Schematic business relationships, separating customer payments from collaboration and technical support.
Reading direction. No quantity or physical timing is implied.
Select a participant or connection. Its explanation stays alongside.
Ready to explore.
A research customer buys products for an agreed use.
analysis
Clinical and other commercial uses require separate assessment.
Atelerix terms of sale
Publication date not recorded; Accessed 2026-11-01
Open original sourceResearch buyer
analysis
A research customer buys products for an agreed use. [4]
Clinical and other commercial uses require separate assessment.
Atelerix terms of sale
Publication date not recorded; Accessed 2026-11-01
Open original sourceThe company sells kits and publishes protocols for their use.
company claim
A published product is not proof of repeat revenue.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix
company claim
The company sells kits and publishes protocols for their use. [15]
A published product is not proof of repeat revenue.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceAuthorised distributors can handle product sales.
company claim
Margin and credit terms are unavailable.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceDistributor
company claim
Authorised distributors can handle product sales. [16]
Margin and credit terms are unavailable.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceA named partner for proposed validation work.
company claim
Partner status does not establish a paying customer.
Atelerix and Frontier Space memorandum
Published 2026-10-27; Accessed 2026-11-01
Open original sourceFrontier Space
company claim
A named partner for proposed validation work. [1]
Partner status does not establish a paying customer.
Atelerix and Frontier Space memorandum
Published 2026-10-27; Accessed 2026-11-01
Open original sourceA direct customer pays Atelerix for products ordered under the company's sale terms.
company claim
No transaction amount or annual revenue is represented.
A direct customer pays Atelerix for products ordered under the company's sale terms.
This arrow represents payment for the order, separate from the materials supplied to the customer.
Payment and fulfilment follow the sale terms; the arrow does not impose a payment-before-dispatch sequence.
Atelerix terms of sale
Publication date not recorded; Accessed 2026-11-01
Open original sourcePayment for products
company claim
Research buyer → Atelerix
A direct customer pays Atelerix for products ordered under the company's sale terms. [4]
- What happens
- A direct customer pays Atelerix for products ordered under the company's sale terms.
- Why it matters
- This arrow represents payment for the order, separate from the materials supplied to the customer.
- What follows
- Payment and fulfilment follow the sale terms; the arrow does not impose a payment-before-dispatch sequence.
No transaction amount or annual revenue is represented.
Atelerix terms of sale
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix supplies preservation materials and instructions to the research customer.
company claim
Suitability depends on sample and procedure.
Atelerix supplies preservation materials and instructions to the research customer.
The instructions describe sample handling; the intended application determines whether cells remain in gel or are released.
The customer must assess recovery for its sample and use; delivery does not establish a biological outcome.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceKits and instructions
company claim
Atelerix → Research buyer
Atelerix supplies preservation materials and instructions to the research customer. [15]
- What happens
- Atelerix supplies preservation materials and instructions to the research customer.
- Why it matters
- The instructions describe sample handling; the intended application determines whether cells remain in gel or are released.
- What follows
- The customer must assess recovery for its sample and use; delivery does not establish a biological outcome.
Suitability depends on sample and procedure.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix offers products through authorised distributors as well as its direct sales route.
company claim
No wholesale price is inferred.
Atelerix offers products through authorised distributors as well as its direct sales route.
The distributor connects the offering with researchers in a local market.
The distributor can offer the products to buyers; wholesale prices and stock arrangements are not inferred.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceProduct distribution
company claim
Atelerix → Distributor
Atelerix offers products through authorised distributors as well as its direct sales route. [16]
- What happens
- Atelerix offers products through authorised distributors as well as its direct sales route.
- Why it matters
- The distributor connects the offering with researchers in a local market.
- What follows
- The distributor can offer the products to buyers; wholesale prices and stock arrangements are not inferred.
No wholesale price is inferred.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceA distributor provides research buyers with local access to Atelerix products.
company claim
Customer purchasing volumes are not established.
A distributor provides research buyers with local access to Atelerix products.
This is a purchasing channel, rather than a separate preservation mechanism or validation result.
The buyer applies the product protocol; actual purchasing volumes remain unestablished.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceProduct resale
company claim
Distributor → Research buyer
A distributor provides research buyers with local access to Atelerix products. [16]
- What happens
- A distributor provides research buyers with local access to Atelerix products.
- Why it matters
- This is a purchasing channel, rather than a separate preservation mechanism or validation result.
- What follows
- The buyer applies the product protocol; actual purchasing volumes remain unestablished.
Customer purchasing volumes are not established.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix is to provide preservation products, protocols and technical support for agreed Frontier Space testing.
company claim
This is planned collaboration, not demonstrated orbital service.
Atelerix is to provide preservation products, protocols and technical support for agreed Frontier Space testing.
The planned work needs a defined preservation method to assess biological samples in proposed mission workflows.
Frontier Space is to help select use cases and execute validation; successful orbital performance is not established.
Atelerix and Frontier Space memorandum
Published 2026-10-27; Accessed 2026-11-01
Open original sourceProducts and support
company claim
Atelerix → Frontier Space
Atelerix is to provide preservation products, protocols and technical support for agreed Frontier Space testing. [1]
- What happens
- Atelerix is to provide preservation products, protocols and technical support for agreed Frontier Space testing.
- Why it matters
- The planned work needs a defined preservation method to assess biological samples in proposed mission workflows.
- What follows
- Frontier Space is to help select use cases and execute validation; successful orbital performance is not established.
This is planned collaboration, not demonstrated orbital service.
Atelerix and Frontier Space memorandum
Published 2026-10-27; Accessed 2026-11-01
Open original sourceFrontier Space is to help select sample use cases and design, integrate and execute the agreed validation work.
company claim
No successful result or cash payment is implied.
Frontier Space is to help select sample use cases and design, integrate and execute the agreed validation work.
The collaboration must assess sample integrity and suitability for later analysis in the proposed mission context.
Validation findings would inform future projects; the memorandum does not establish successful results or a product sale.
Atelerix and Frontier Space memorandum
Published 2026-10-27; Accessed 2026-11-01
Open original sourceValidation collaboration
company claim
Frontier Space → Atelerix
Frontier Space is to help select sample use cases and design, integrate and execute the agreed validation work. [1]
- What happens
- Frontier Space is to help select sample use cases and design, integrate and execute the agreed validation work.
- Why it matters
- The collaboration must assess sample integrity and suitability for later analysis in the proposed mission context.
- What follows
- Validation findings would inform future projects; the memorandum does not establish successful results or a product sale.
No successful result or cash payment is implied.
Atelerix and Frontier Space memorandum
Published 2026-10-27; Accessed 2026-11-01
Open original sourceComplete participants, relationships and sources
Research buyer
analysis
A research customer buys products for an agreed use. [4]
Clinical and other commercial uses require separate assessment.
Atelerix terms of sale
Publication date not recorded; Accessed 2026-11-01
Open original sourceAtelerix
company claim
The company sells kits and publishes protocols for their use. [15]
A published product is not proof of repeat revenue.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceDistributor
company claim
Authorised distributors can handle product sales. [16]
Margin and credit terms are unavailable.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceFrontier Space
company claim
A named partner for proposed validation work. [1]
Partner status does not establish a paying customer.
Atelerix and Frontier Space memorandum
Published 2026-10-27; Accessed 2026-11-01
Open original sourcePayment for products
company claim
Research buyer → Atelerix
A direct customer pays Atelerix for products ordered under the company's sale terms. [4]
- What happens
- A direct customer pays Atelerix for products ordered under the company's sale terms.
- Why it matters
- This arrow represents payment for the order, separate from the materials supplied to the customer.
- What follows
- Payment and fulfilment follow the sale terms; the arrow does not impose a payment-before-dispatch sequence.
No transaction amount or annual revenue is represented.
Atelerix terms of sale
Publication date not recorded; Accessed 2026-11-01
Open original sourceKits and instructions
company claim
Atelerix → Research buyer
Atelerix supplies preservation materials and instructions to the research customer. [15]
- What happens
- Atelerix supplies preservation materials and instructions to the research customer.
- Why it matters
- The instructions describe sample handling; the intended application determines whether cells remain in gel or are released.
- What follows
- The customer must assess recovery for its sample and use; delivery does not establish a biological outcome.
Suitability depends on sample and procedure.
Atelerix BeadReady product and displayed UK prices
Publication date not recorded; Accessed 2026-11-01
Open original sourceProduct distribution
company claim
Atelerix → Distributor
Atelerix offers products through authorised distributors as well as its direct sales route. [16]
- What happens
- Atelerix offers products through authorised distributors as well as its direct sales route.
- Why it matters
- The distributor connects the offering with researchers in a local market.
- What follows
- The distributor can offer the products to buyers; wholesale prices and stock arrangements are not inferred.
No wholesale price is inferred.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceProduct resale
company claim
Distributor → Research buyer
A distributor provides research buyers with local access to Atelerix products. [16]
- What happens
- A distributor provides research buyers with local access to Atelerix products.
- Why it matters
- This is a purchasing channel, rather than a separate preservation mechanism or validation result.
- What follows
- The buyer applies the product protocol; actual purchasing volumes remain unestablished.
Customer purchasing volumes are not established.
Atelerix distributor network
Publication date not recorded; Accessed 2026-11-01
Open original sourceProducts and support
company claim
Atelerix → Frontier Space
Atelerix is to provide preservation products, protocols and technical support for agreed Frontier Space testing. [1]
- What happens
- Atelerix is to provide preservation products, protocols and technical support for agreed Frontier Space testing.
- Why it matters
- The planned work needs a defined preservation method to assess biological samples in proposed mission workflows.
- What follows
- Frontier Space is to help select use cases and execute validation; successful orbital performance is not established.
This is planned collaboration, not demonstrated orbital service.
Atelerix and Frontier Space memorandum
Published 2026-10-27; Accessed 2026-11-01
Open original sourceValidation collaboration
company claim
Frontier Space → Atelerix
Frontier Space is to help select sample use cases and design, integrate and execute the agreed validation work. [1]
- What happens
- Frontier Space is to help select sample use cases and design, integrate and execute the agreed validation work.
- Why it matters
- The collaboration must assess sample integrity and suitability for later analysis in the proposed mission context.
- What follows
- Validation findings would inform future projects; the memorandum does not establish successful results or a product sale.
No successful result or cash payment is implied.
Atelerix and Frontier Space memorandum
Published 2026-10-27; Accessed 2026-11-01
Open original sourceScope. No revenue forecast, contract value or profit margin is implied. The space partnership has no disclosed payment terms.
Competitors and alternatives
Preservation products and transport substitutes identified in this search.
| Topic | Evidence and scope |
|---|---|
| BioLife, now part of Repligen | BioLife markets a non-frozen preservation medium for cells and tissues at 2 to 8 degrees C. It is an alternative to evaluate for a matched sample and journey. [11] company claim A medium is not a hydrogel kit. Published operating conditions and sample compatibility differ. |
| Thermo Fisher Recovery | Gibco Recovery is a ready-to-use freezing medium for mammalian cells. It represents a cryopreservation workflow alternative. [20] company claim Comparison requires freezing, storage, thawing and functional recovery costs, not reagent price alone. |
| Cryoport Express | Cryoport offers a liquid-nitrogen dry-vapour shipping system for biological materials. This is a logistics substitute, not a directly interchangeable consumable. [12] company claim No matched cost or sample-quality trial against Atelerix was obtained. |
| Competitive test | Compare usable sample recovery and downstream assay performance under the same shipping conditions, alongside the laboratory’s existing process. [15] [11] [20] analysis Identified alternatives are not an exhaustive global competitor list. |
Funding and financial position
Disclosed financing events and unresolved financial information.
| Topic | Evidence and scope |
|---|---|
| Atelerix financing | Atelerix announced GBP750,000 with ACF Investors and o2h Ventures in an article whose body is dated 28 January 2025. [17] company claim The URL contains 2024/09; N8 describes February 2025. These are not treated as separate rounds. Completion documents and cash receipt were not inspected. |
| Earlier financing | N8 reports GBP500,000 in February 2024 and GBP700,000 in May 2019. [18] company claim Historical amounts are not current cash, valuation or runway. No cumulative total is calculated. |
| Cash and ownership | Not established. Current cash, debt, cap table, grant balances and monthly cash burn were not obtained. Not established A round announcement cannot establish runway. |
| Public alternatives | BioLife historical financial statements and Cryoport filings provide operating context. Repligen completed its acquisition of BioLife on 6 October 2026. [8] [10] [9] analysis Public financial series below are context, not valuations or funding estimates for Atelerix. |
CAPEX, OPEX and price benchmarks
Separate customer purchase costs, public-peer expenditure and unavailable startup costs.
| Topic | Evidence and scope |
|---|---|
| Atelerix customer price | The BeadReady page displays GBP175 to GBP1,745 excluding VAT across pack options and advertises a starting price of GBP34 per vial. [15] company claim Displayed UK list prices on 1 November 2026; no pack-to-price mapping or realised selling price is inferred. Freight, tax, labour and recovery losses are additional. |
| Alternative reagent price | BioLife’s US store displays USD70 for 10 mL, USD330 for 100 mL and USD1,540 for a 500 mL bottle of HypoThermosol FRS. [11] company claim List-price snapshot, not a quote. The store states a USD200 minimum order. Volumes are not equivalent to BeadReady encapsulations; no currency conversion or per-sample saving is inferred. |
| Public-peer OPEX | BioLife reports USD78.720 million of operating expenses for 2025 and USD54.573 million for 2024. [8] verified Continuing operations; excludes cost of revenue. 2025 includes acquired in-process R&D expense. Not a startup budget or an industry average. |
| Public-peer CAPEX | BioLife reports property and equipment cash purchases of USD9.478 million in 2025 and USD3.227 million in 2024. [8] verified Consolidated cash-flow scope includes discontinued operations, unlike its continuing-operations revenue. No CAPEX/revenue ratio is calculated from these mismatched scopes. |
| Atelerix manufacturing cost | Not established. The bill of materials, production capacity, facility expenditure, quality-control cost and gross margin were not obtained. Not established Customer list prices do not reveal manufacturing OPEX. |
| Customer cost model | Compare reagent, labour, packaging, transport and repeat-work cost per usable sample. Record actual recovery and workflow time before estimating savings. [15] [4] analysis No numerical savings estimate is made without matched quotations and measured performance. |
Supply chain and dependencies
Input categories, product channels and missing contractual evidence.
| Topic | Evidence and scope |
|---|---|
| Inputs | The disclosed technology uses alginate hydrogel; BeadReady includes gels and gelation and dissolution buffers. [18] [15] company claim Input categories are known. Named upstream suppliers, prices and substitute qualification times are not. |
| Quality and capacity | Atelerix states that batches are quality tested and components are pharmaceutical grade and GMP sourced. [15] company claim This is product-page wording, not an inspected factory audit, release record or capacity assessment. |
| Sales channels | Atelerix describes a distributor network and offers direct product ordering. [16] [15] company claim Distributor territories, exclusivity, stock commitments and margins were not obtained. |
| Continuity | Not established. Supplier contracts, single-source exposure, safety stock, shelf-life records and contingency qualification plans were not obtained. Not established Do not equate an unnamed input with an assured supply. |
Industry drivers
Evidence-backed reasons to investigate demand and adoption.
| Topic | Evidence and scope |
|---|---|
| Distributed laboratory work | Atelerix’s selected testimonials describe sample movement between research and development sites. Easier handling could matter where sample function survives the journey. [19] analysis Selected company-hosted testimonials do not establish market-wide demand or measured savings. |
| Space research | The Frontier Space memorandum creates a proposed route to testing preservation during space research, with launch opportunities targeted for 2027. [1] company claim A target and collaboration are not a booked launch, successful experiment or purchase commitment. |
| Channel expansion | A distributor route can make local sourcing easier for laboratory buyers. [16] analysis Reach does not establish sell-through, repeat orders or favourable channel economics. |
Adoption blockers
Constraints and evidence that could change the commercial assessment.
| Topic | Evidence and scope |
|---|---|
| Sample-specific suitability | A practical decision needs acceptable recovery and downstream function for the buyer’s own sample and protocol. [15] analysis Marketing claims should not be extended to every cell, tissue or transit condition. |
| Permitted use | Published standard terms limit use to internal research; additional commercial use requires a separate licence. [4] company claim Terms are not a finding about every bespoke agreement or regulatory status. |
| Unproven space economics | The mission collaboration aims to reduce preservation-related mass and complexity. The cost benefit is still to be tested. [1] analysis No verified mission saving, orbital performance or commercial order value was obtained. |
| Scale economics | Not established. Validated volume pricing, lot yields and production expansion costs were not obtained. Not established Without these, a low-CAPEX or high-margin thesis is unsupported. |
Customer, investor and public appetite
Different signals of interest, with their evidential limits.
| Topic | Evidence and scope |
|---|---|
| Customer references | Atelerix publishes selected testimonials attributed to research organisations, including DefiniGEN, now Pixl Bio, and the LV Prasad Eye Institute. [19] company claim These are company-curated statements; order size, repeat purchasing and independent reference interviews were not obtained. |
| Investor interest | The announced GBP750,000 round identifies investor participation. [17] company claim Financing interest is not customer demand or proof that the technology works. |
| Commercial milestone | A paid repeat order with defined acceptance criteria would be stronger commercial evidence than a memorandum alone. [1] [4] analysis This is a proposed test, not a reported contract. |
| Public acceptance | Not established. No relevant representative survey or public consultation measuring acceptance of this product was obtained. Not established Press coverage and investor funding are not substitutes for public sentiment data. |
Sellers, buyers and potential exits
Who sells, who uses the product and which relationships remain unknown.
| Topic | Evidence and scope |
|---|---|
| Seller and channel | Atelerix sells products directly and through authorised distributors. [4] [16] company claim The split of revenue by channel is not disclosed here. |
| User, buyer and payer | Researchers may evaluate the product while a laboratory or procurement team places the order. Treat the budget holder and user as separate roles to confirm. [19] [4] analysis This is an illustrative purchasing structure, not a verified organisation chart for a named customer. |
| Space counterpart | Frontier Space is a named validation partner. Atelerix is to supply products, protocols and technical support for agreed projects. [1] company claim No payment amount, exclusivity or minimum purchase was disclosed. |
| Acquisition interest | Not established. No evidence of acquisition interest in Atelerix was obtained. Not established Listed comparators are not labelled as prospective buyers of the company. |
| Sector transaction | Repligen completed its acquisition of BioLife in October 2026. This is an observed transaction in adjacent preservation products. [9] verified It does not establish acquisition interest in Atelerix or an appropriate valuation multiple. |
Public-company context · 2026-11-01
Listed companies around this market
Current listed context and historical standalone preservation financials. No company here is established as an Atelerix supplier, customer or prospective acquirer. Price movement is separate from demand evidence.
A listed company's share price reflects its whole business. It does not establish demand for this startup, a supplier relationship or a private valuation.
BioLife Solutions, historical standalone
Comparator · analysis
Preservation media provide a product-level alternative. Repligen acquired BioLife on 6 October 2026; these are earlier standalone financials. [8] [11] [9] [13]
BLFS last traded on 5 October 2026 and was suspended from 7 October. No current BLFS price chart is shown. Historical figures are not Repligen group results or Atelerix costs.
A supported stock-chart listing has not been established.
Revenue
Continuing operations as recast in the 2025 annual report. Units: USD thousand.
| Period | Reported value | Filing and evidence |
|---|---|---|
| 2024-01-01 to 2024-12-31 | 74,647 USD thousand | 2026-02-26 · verified Consolidated Statements of Operations: Revenue, annual 2024 column [8] |
| 2025-01-01 to 2025-12-31 | 96,214 USD thousand | 2026-02-26 · verified Consolidated Statements of Operations: Revenue, annual 2025 column [8] |
Excludes divested businesses; not Atelerix revenue.
Operating expenses
Continuing operations, excluding cost of revenue. Units: USD thousand.
| Period | Reported value | Filing and evidence |
|---|---|---|
| 2024-01-01 to 2024-12-31 | 54,573 USD thousand | 2026-02-26 · verified Consolidated Statements of Operations: Total operating expenses, annual 2024 column [8] |
| 2025-01-01 to 2025-12-31 | 78,720 USD thousand | 2026-02-26 · verified Consolidated Statements of Operations: Total operating expenses, annual 2025 column [8] |
2025 includes acquired in-process R&D. Accounting expense is not cash burn.
Calculated comparisons
2025 operating expenses / revenue: 81.82% analysis · calculated, rounded to 2 decimal places
100 × 78,720 ÷ 96,214. Operating expenses / Revenue, period ending 2025-12-31. [8]
Derived from the same continuing-operations period. Includes acquired in-process R&D; excludes cost of revenue. Not a startup benchmark margin.
Cryoport
Industry context · analysis
Cryogenic logistics and shipping equipment offer context for an alternative transport workflow. [10] [12]
A services and equipment group, not an interchangeable hydrogel business or established Atelerix trading partner.
View Cryoport on TradingView. External price data may be delayed or unavailable; filing evidence is shown below.
Revenue
Continuing operations, with CRYOPDP excluded for all presented periods in the 2025 report. Units: USD thousand.
| Period | Reported value | Filing and evidence |
|---|---|---|
| 2024-01-01 to 2024-12-31 | 156,769 USD thousand | 2026-03-05 · verified Consolidated Statements of Operations: Total revenue, year ended 31 December 2024 [10] |
| 2025-01-01 to 2025-12-31 | 176,177 USD thousand | 2026-03-05 · verified Consolidated Statements of Operations: Total revenue, year ended 31 December 2025 [10] |
Use the recast 2024 comparative, not previously reported group revenue before divestiture.
Repligen
Industry context · analysis
Current listed parent of the BioLife preservation product business. [9] [14]
A broader bioprocessing group. The stock is not a pure measure of preservation demand, and the historical BioLife figures above are not Repligen financials.
View Repligen on TradingView. External price data may be delayed or unavailable; filing evidence is shown below.
Comparable reported financial series have not been established for this view.
Competitive landscape · 2026-11-01
Who else solves this?
Alternatives to non-frozen hydrogel cell preservation: chilled media, established freezing media and cryogenic transport. These compete at different steps of a validated cell-handling workflow.
Comparison lens. HypoThermosol is the closest non-frozen preservation alternative here. Recovery and mFreSR retain freezing and thawing; Cryoport is transport infrastructure, not competing preservation chemistry. Cell type, storage interval and post-storage function determine substitutability. analysis
Direct competitor · Bothell, USA
BioLife HypoThermosol FRS
Non-frozen cell and tissue preservation medium for storage and shipment at 2 to 8 degrees Celsius.
- Difference
- Shares the goal of avoiding freeze-thaw, using a liquid medium rather than Atelerix hydrogel encapsulation. Temperature and sample compatibility still differ.
- Maturity
- Commercial catalogue product. cGMP manufacture and an FDA master file are stated; a master file is not product approval.
- Economics
- US catalogue observed at USD 330 per 100 ml bottle, before delivery. No equivalent Atelerix volume or cell yield supports a savings calculation.
- Funding / ownership
- BioLife Solutions is the named supplier; current ownership and product-level funding were not established from this catalogue.
No matched viability, function or transport-duration comparison across cell types.
analysis
Sources and dates
BioLife HypoThermosol FRS catalogue and US prices (published date not stated; accessed 2026-11-01)
Established supplier · International Thermo Fisher catalogue
Gibco Recovery
Ready-to-use DMSO-containing cell-culture freezing medium.
- Difference
- Preserves cells through a frozen workflow rather than Atelerix non-frozen storage. Existing freezer protocols can favour retention.
- Maturity
- Catalogued research-use product; not a blanket clinical-cell-therapy authorisation.
- Economics
- Consumable price alone omits freezing, storage, shipping and recovery costs. The retrieved locale showed a non-UK price; no converted benchmark is used.
- Funding / ownership
- Gibco is offered by Thermo Fisher; product-specific funding is undisclosed in this source.
A cell-line freezing protocol does not establish suitability for every tissue or therapeutic product.
analysis
Sources and dates
Gibco Recovery freezing-medium catalogue (published date not stated; accessed 2026-11-01)
Alternative approach · International supplier; product-specific sales territories not audited
STEMCELL mFreSR
Serum-free, DMSO-containing medium for freezing human embryonic and induced pluripotent stem cells.
- Difference
- A defined stem-cell freezing alternative, not an interchangeable general cell-storage medium.
- Maturity
- Commercial catalogue product with associated protocols and manufacturer thawing data.
- Economics
- Requires a freezing and thawing workflow; matched total cost and post-thaw functional yield are unestablished.
- Funding / ownership
- STEMCELL is the named supplier. Product-level funding and current ownership detail were not verified here.
Manufacturer comparisons with reported thawing methods are not a head-to-head Atelerix trial.
analysis
Sources and dates
STEMCELL mFreSR product and intended cell types (published date not stated; accessed 2026-11-01)
Alternative approach · International logistics offering; route qualification required
Cryoport Express Standard
Liquid-nitrogen dry-vapour shipper with condition monitoring for biological payloads.
- Difference
- Supports continued cryogenic logistics rather than replacing cell-preservation chemistry. It can complement a freezing medium.
- Maturity
- Marketed shipping system with a manufacturer-stated hold-time specification.
- Economics
- Quotation required; transport, monitoring, preparation and route qualification must be included. No matched Atelerix lane comparison is established.
- Funding / ownership
- Cryoport Systems supplies the service; current product investment and cash allocation are not disclosed on this page.
A qualified container temperature is not proof of cell recovery or potency after transport.
analysis
Sources and dates
Cryoport Express Standard product and quotation route (published date not stated; accessed 2026-11-01)
Coverage limits. Bounded primary-source comparison, not an exhaustive census or independent performance test. Product-specific funding, current cash, contract pricing and head-to-head outcomes are unknown unless explicitly stated. Adjacent tools may complement the company rather than replace it.
Sources
- 1Frontier Space partnership announcement
company | Published 2026-10-27 | Accessed 2026-11-01
- 2Companies House: Atelerix Limited
registry | Published undated | Accessed 2026-11-01
- 3Companies House: control statements
registry | Published undated | Accessed 2026-11-01
- 4Current terms of sale
company terms | Published undated | Accessed 2026-11-01
- 5Company history
company | Published undated | Accessed 2026-11-01
- 6Company explanation of preservation
company | Published undated | Accessed 2026-11-01
- 7Branco et al., Bioengineering 9(12), 805
peer-reviewed paper | Published 2022-12-14 | Accessed 2026-11-01
- 8BioLife Solutions 2025 Form 10-K
regulatory filing | Published 2026-02-26 | Accessed 2026-11-01
- 9Repligen Form 8-K: completed BioLife acquisition
regulatory filing | Published 2026-10-06 | Accessed 2026-11-01
- 10Cryoport 2025 Form 10-K
regulatory filing | Published 2026-03-05 | Accessed 2026-11-01
- 11BioLife US store: HypoThermosol FRS prices
company | Published undated | Accessed 2026-11-01
- 12Cryoport Express Standard shipping system
company | Published undated | Accessed 2026-11-01
- 13Nasdaq corporate action: BLFS last trading date and suspension
exchange notice | Published 2026-10-05 | Accessed 2026-11-01
- 14Repligen acquisition FAQ and current Nasdaq listing
company | Published undated | Accessed 2026-11-01
- 15Atelerix BeadReady product and displayed UK prices
company | Published undated | Accessed 2026-11-01
- 16Atelerix distributor network
company | Published undated | Accessed 2026-11-01
- 17Atelerix funding announcement, body dated 28 January 2025
company | Published 2025-01-28 | Accessed 2026-11-01
- 18N8 Research Partnership: Atelerix history
university partnership | Published undated | Accessed 2026-11-01
- 19Atelerix selected customer testimonials
company | Published undated | Accessed 2026-11-01
- 20Thermo Fisher: Recovery Cell Culture Freezing Medium
company | Published undated | Accessed 2026-11-01